AtriCure (NASDAQ:ATRC) Insider Vinayak Doraiswamy Sells 6,000 Shares

AtriCure, Inc. (NASDAQ:ATRC) insider Vinayak Doraiswamy sold 6,000 shares of the business’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total transaction of $233,280.00. Following the transaction, the insider owned 86,511 shares of the company’s stock, valued at $3,363,547.68. This trade represents a 6.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

AtriCure Trading Down 1.8%

AtriCure stock opened at $40.15 on Friday. The stock has a market cap of $2.04 billion, a P/E ratio of 191.20 and a beta of 1.24. AtriCure, Inc. has a fifty-two week low of $25.36 and a fifty-two week high of $43.18. The firm’s fifty day moving average price is $30.91 and its 200-day moving average price is $31.29. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.18 and a current ratio of 4.22.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The company had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter last year, the company earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities research analysts forecast that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On AtriCure

A number of large investors have recently modified their holdings of the company. Handelsbanken Fonder AB grew its position in AtriCure by 12.3% during the second quarter. Handelsbanken Fonder AB now owns 22,800 shares of the medical device company’s stock valued at $638,000 after acquiring an additional 2,500 shares during the last quarter. Tactive Advisors LLC bought a new position in shares of AtriCure during the 2nd quarter valued at $374,000. Assenagon Asset Management S.A. purchased a new position in AtriCure in the 2nd quarter worth $1,744,000. Harbor Investment Advisory LLC bought a new stake in AtriCure in the second quarter worth $40,000. Finally, Bank of America Corp DE boosted its position in AtriCure by 13.7% during the first quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock valued at $21,927,000 after buying an additional 92,830 shares during the period. 99.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. UBS Group lowered their target price on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday. Canaccord Genuity Group lifted their target price on shares of AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Zacks Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 24th. Finally, Raymond James Financial set a $52.00 price target on shares of AtriCure in a report on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $48.50.

Key AtriCure News

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: UBS lowered its price target from $55 to $50 but maintained a Buy rating, implying substantial upside from recent trading levels. The revised target remains supportive of the long-term outlook for AtriCure’s medical-device business. UBS price target report
• Positive Sentiment: AtriCure recently exceeded quarterly expectations, reporting earnings per share of $0.18 versus an analyst estimate of $0.13 and revenue of $153.6 million versus estimates of $151.8 million. Results also improved from a loss in the year-ago period, supporting the company’s growth and profitability narrative. AtriCure earnings report
• Neutral Sentiment: Recent coverage is focused on whether options activity signals an unusually large upcoming move in ATRC. No specific direction is established, but elevated options interest may contribute to short-term volatility. AtriCure options activity article
• Neutral Sentiment: Investors are also reviewing new share-registration filings. Such filings can provide AtriCure with financing flexibility, although the potential for future share issuance may raise dilution concerns. AtriCure share registration article
• Negative Sentiment: Several insiders sold shares: Director Sven Wehrwein reduced his holdings by about 38%, while executives Justin J. Noznesky and Vinayak Doraiswamy cut their positions by approximately 6% each. The sales, totaling roughly $1.42 million, may weigh on sentiment, particularly after ATRC’s strong recent run.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.